
Join to View Full Profile
PO BoxBldg BAtlanta, GA 30322
Phone+1 404-778-6874
Dr. Sanda is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Martin Sanda is Professor and Chair of Urology at Emory Healthcare in Atlanta, GA and is affiliated with multiple hospitals in the area, including Emory University Hospital, Emory Saint Joseph's Hospital of Atlanta, and others. He received his medical degree from Columbia University College of Physicians & Surgeons, completed his Urology residency at Johns Hopkins, and has been in practice 25 years. He specializes in urological oncology with focus on prostate cancer, and has managed the care and treatment of over 2500 men with newly diagnosed prostate cancer.
Education & Training
Johns Hopkins UniversityResidency, Urology, 1991 - 1995
National Cancer InstituteFellowship, Tumor Immunology, 1989 - 1991
Virginia Commonwealth University Health SystemResidency, Surgery, 1987 - 1989
Columbia University Vagelos College of Physicians and SurgeonsClass of 1987
Certifications & Licensure
GA State Medical License 2013 - 2026
MA State Medical License 2003 - 2014
MI State Medical License 1995 - 2005
MD State Medical License 1989 - 1995
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification FirstNet (CQM), Cerner Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification FirstNet (Clinical), Cerner Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification HealtheLife and PowerChart, Cerner Corporation, 2014, 2016-2017
Clinical Trials
- Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer Start of enrollment: 2002 Sep 01
- Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
- Observation or Radical Treatment in Patients With Prostate Cancer Start of enrollment: 2007 Dec 06
Publications & Presentations
PubMed
- Does the VA Risk Analysis Index Overestimate Frailty in Patients with Localized Prostate Cancer?Pranay Manda, Siddharth Marthi, Ernest Morton, Mihir Patel, Dattatraya Patil
Urology Practice. 2026-01-20 - Cross-cultural adaptation and psychometric validation of the Finnish version of the Expanded Prostate Cancer Index Composite-26 for patients with localised prostate ca...Otto Ettala, Robin Bergroth, Jarno Riikonen, Peter Boström, Juha Koskimäki
Scandinavian Journal of Urology. 2025-08-27 - Sociodemographic Features, Health Care Costs, and Treatment Implications of Genomic Classifier Testing for Localized Prostate Cancer in the United States.James R Janopaul-Naylor, Dattatraya Patil, Shreyas Joshi, Martin G Sanda, Nikhil Sebastian
JCO Precision Oncology. 2025-08-01
Journal Articles
- Impact of Prebiopsy Magnetic Resonance Imaging of the Prostate on Cancer Detection and Treatment PatternsMartin G Sanda, Christopher P Filson, Urologic Oncology
Press Mentions
Newly Discovered Immune Cell Revolutionizes Cancer TreatmentsJanuary 6th, 2025
Immune Cell Find Boosts Cancer Immunotherapy HopesOctober 26th, 2024
Immune Cell Discovery Offers New Potential for Cancer ImmunotherapyOctober 25th, 2024
Grant Support
- Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas SouthwesternEMORY UNIVERSITY2005–2028
- Effectiveness Of Robotic Compared To Standard Prostatectomy For Prostate CancerNational Institute Of Biomedical Imaging And Bioengineering2009–2010
- Effectiveness Of Early Stage Prostate Cancer TreatmentNational Cancer Institute2009–2010
- University Of Michigan O'Brien Center For Urology ResearchNational Institute Of Diabetes And Digestive And Kidney Diseases2007
- Survivor Qol/Spouse Satisfaction After Prostate TherapyNational Cancer Institute2004–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









